Microencapsulated islet allografts in diabetic NOD mice and nonhuman primates.
CONCLUSIONS: The evidence suggested that hypoxia was a major factor for damage to encapsulated islets in vivo. To achieve long-term function, new approaches must be developed to increase the oxygen supply to microencapsulated islets and/or identify donor insulin-secreting cells which can tolerate hypoxia.
PMID: 32894560 [PubMed - as supplied by publisher]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Bone Graft | Diabetes | Drugs & Pharmacology | Endocrinology | Insulin | Stem Cell Therapy | Stem Cells | Transplants